More than a hundred endocrinologists from all over Spain and national and international speakers participate in these acts on innovation and new diabetes therapies.
Although there is a wide range of treatments for type 2 diabetes (DM2), 50% of patients do not reach their blood sugar control objectives due, in part, to the evolution of the disease.
Hence the need, according to experts, of new innovative approaches to the treatment of this pathology.Some of these objectives were discussed in the progress days, which have recently met, in Valencia, more than one hundred endocrinologists from all over Spain and that have been promoted by the Boehringer Ingelheim and Lilly Alliance in Diabetes.
Likewise, the conference served to present, officially to the specialists, the new SGLT2 inhibitor for the treatment of type 2 diabetes in adults: Pagliflozine (Jardiance).
During the meeting, Dr. Sharona Azriel, specialist at the Endocrinology Service of the Infanta Sofía University Hospital and the Quirón University Hospital (Madrid), explained that as important as choosing the appropriate pharmacological treatment is “to implement an early therapeutic intervention and move towards combinations thatThey address the different pathogenic mechanisms of the disease.The existing therapeutic arsenal favors a customization in the management of pathology according to the characteristics of the patient, clinical circumstances, pathophysiological defects and ideally by characterization of the genotype. ”
The prevention of obesity was also emphasized because it is a factor that contributes in the origins of the disease, to the point that “a population without overweight or obesity would be a population without type 2 diabetes or, at least, the cases would beExceptional, ”said Dr. Francisco Tinahones, head of the Regional Endocrinology and Nutrition Service and Virgen de la Victoria (Malaga).
In this sense, the expert highlighted the role of SGLT2 inhibitory drugs since "not only glycemia levels do not improve but that they get a descent of weight and blood pressure, very beneficial effects on the patient with DM2".Thus, among this kind of drugs there was talk of the SGLT2 inhibitor.Recently marketed in Spain, Pagliflozina (Jardiance).
Its characteristics make it especially indicated for patients under 65, with obesity or overweight, even in patients with very bad metabolic control.“Pagliflozina has shown a lot of effectiveness and a high degree of safety in patients under 65 years.
On the other hand, it has been shown that it produces weight descents around two kilos when compared to placebo and that their effectiveness is greater in subjects with bad metabolic control, ”explained Dr. Tinehones.It should be noted that Pagliflozina is the third drug of the Boehringer Ingelheim and Lilly alliance in diabetes that is marketed in Spain.
It is presented in the form of oral tablet (available at 10 mg and 25 mg), in a single daily dose for the treatment of DM2 in the adult, when diet and exercise alone do not provide sufficient glycemic control.It is indicated in monotherapy, when metformin is not tolerated and combined with other hypoglycemic, including insulin, when they are not enough for blood glucose control.
